These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 22840259)
1. What should drive the choice of allergen for immunotherapy in polysensitized patients? Ciprandi G; Incorvaia C; Puccinelli P; Dell'Albani I; Frati F Ann Allergy Asthma Immunol; 2012 Aug; 109(2):148-9. PubMed ID: 22840259 [No Abstract] [Full Text] [Related]
2. What will allergen immunotherapy look like in the future? Nelson HS Ann Allergy Asthma Immunol; 2012 Aug; 109(2):87-9. PubMed ID: 22840246 [No Abstract] [Full Text] [Related]
3. Allergen immunotherapy (AIT) for the multiple-pollen sensitive patient. Nelson HS Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1443-1451. PubMed ID: 27687128 [TBL] [Abstract][Full Text] [Related]
4. Some highlights of the first century of immunotherapy. Nelson HS Ann Allergy Asthma Immunol; 2011 Nov; 107(5):417-21. PubMed ID: 22018612 [No Abstract] [Full Text] [Related]
5. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. Calderón MA; Cox L; Casale TB; Moingeon P; Demoly P J Allergy Clin Immunol; 2012 Apr; 129(4):929-34. PubMed ID: 22244595 [TBL] [Abstract][Full Text] [Related]
6. Preparing and mixing allergen vaccines for subcutaneous immunotherapy. Nelson HS Clin Allergy Immunol; 2008; 21():303-20. PubMed ID: 18828513 [No Abstract] [Full Text] [Related]
9. [GUIDE TO ALLERGEN IMMUNOTHERAPY FOR MITE ALLERGY]. Gotoh M Arerugi; 2017; 66(6):788-791. PubMed ID: 28701643 [No Abstract] [Full Text] [Related]
10. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis. Rossi RE; Monasterolo G; Coco G; Operti D Int Arch Allergy Immunol; 2005 Oct; 138(2):105-10. PubMed ID: 16174987 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients. Rossi RE; Monasterolo G Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445 [TBL] [Abstract][Full Text] [Related]
17. Specific immunotherapy, one century later. Passalacqua G; Bush RK Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):551-3. PubMed ID: 21971328 [No Abstract] [Full Text] [Related]
18. Guidelines for using pollen cross-reactivity in formulating allergen immunotherapy. Weber RW J Allergy Clin Immunol; 2008 Jul; 122(1):219-21. PubMed ID: 18602577 [No Abstract] [Full Text] [Related]